Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. Among authors: robinson bg. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Capdevila J, et al. Thyroid. 2024 Mar;34(3):347-359. doi: 10.1089/thy.2023.0463. Epub 2024 Jan 23. Thyroid. 2024. PMID: 38062732 Free PMC article. Clinical Trial.
Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol.
Lawless AK, Kumar S, Bindra J, Sywak M, Chou A, Turchini J, Papachristos A, Wijewardene A, Sidhu S, Ahadi M, Tacon L, Glover A, Clark K, Tsang V, Pang L, Clifton-Bligh RJ, Robinson B, Gill AJ, Guminski A, Eade T, Gild ML. Lawless AK, et al. Asia Pac J Clin Oncol. 2024 Dec;20(6):681-689. doi: 10.1111/ajco.14106. Epub 2024 Aug 15. Asia Pac J Clin Oncol. 2024. PMID: 39145924 Review.
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA. Wirth LJ, et al. J Clin Oncol. 2024 Sep 20;42(27):3187-3195. doi: 10.1200/JCO.23.02503. Epub 2024 Aug 2. J Clin Oncol. 2024. PMID: 39094065 Free PMC article. Clinical Trial.
Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline.
Sundram F, Robinson BG, Kung A, Lim-Abrahan MA, Bay NQ, Chuan LK, Chung JH, Huang SM, Hsu LC, Kamaruddin N, Cheah WK, Kim WB, Koong SS, Lin HD, Mangklabruks A, Paz-Pacheco E, Rauff A, Ladenson PW. Sundram F, et al. Among authors: robinson bg. Thyroid. 2006 May;16(5):461-9. doi: 10.1089/thy.2006.16.461. Thyroid. 2006. PMID: 16756468
286 results